Compare CRT & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRT | POM |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | China |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Other Specialty Stores |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 47.2M |
| IPO Year | N/A | N/A |
| Metric | CRT | POM |
|---|---|---|
| Price | $9.87 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.0K | ★ 1.1M |
| Earning Date | 03-12-2026 | 05-03-2026 |
| Dividend Yield | ★ 6.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $0.19 |
| 52 Week High | $13.31 | $6.43 |
| Indicator | CRT | POM |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 47.44 |
| Support Level | $9.51 | $0.28 |
| Resistance Level | $9.99 | $0.42 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 68.35 | 43.51 |
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.